Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: Potentially Inappropriate Medications (PIMs) and Drug-Drug Interactions (DDIs) among geriatrics are a prominent issue and place a considerable burden on the quality health outcome. This study aimed to assess PIMs and DDIs particularly among geriatric cardiac elderly patients attending the outpatient department of a tertiary care hospital of Nepal.

Methodology: A prospective cross-sectional study was conducted on geriatrics patients (≥ 65 years) attending the cardiology out-patient department of Bharatpur Central Hospital, Nepal. Beers criteria were used to assess PIM, and Medscape software was employed to assess DDIs. Regression analysis was performed to identify the predictors of PIM and DDIs experienced by patients.

Results: A total of 140 geriatric patients were enrolled in the study. A total of 683 drugs were prescribed to them, with an average of 4.59 medications per patient. 23.6% and 65% of patients were found to be prescribed PIMs and encountered DDIs, respectively. Proton Pump Inhibitors (PPI) (66.67%) were the most prescribed PIMs and involved in identified DDIs. The removal of PIMs was calculated to reduce 11.72% of the cost of patients prescribed PIMs and 19.88% of identified DDIs. The number of medications prescribed was found to be a significant predictor for PIM (Odd Ratio: 1.352) and DDIs (Odd Ratio: 2.217) encountered.

Conclusion: This study highlights the concerning prevalence of potentially inappropriate medication and drug-drug interactions among ambulatory cardiac elderly patients. Integration of regular medication audits and evidence-based prescribing practices is essential to optimize pharmacological management and enhance patient safety.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399338PMC
http://dx.doi.org/10.1002/agm2.70034DOI Listing

Publication Analysis

Top Keywords

drug-drug interactions
12
prescribed pims
12
inappropriate medications
8
tertiary care
8
central hospital
8
hospital nepal
8
ddis
8
cardiac elderly
8
elderly patients
8
patients prescribed
8

Similar Publications

Coproporphyrin (CP)-I has emerged as a promising endogenous biomarker for investigating organic anion transporting polypeptide (OATP) 1B1/1B3-mediated drug-drug interactions. The precursor eliminated analytical (PEA) method selectively quantifies the endogenous CP-I that should be monitored, whereas the precursor oxidized analytical method quantifies the total CP-I concentration by converting all precursors into CP-I during the sample preparation process. Plasma concentrations of CP-I exhibited a greater magnitude of change in response to rifampicin treatment compared with its precursor in a previous monkey study.

View Article and Find Full Text PDF

Background: Janus kinase inhibitors (JAKIs) are small molecules used orally to treat inflammatory and hematological disorders. They have demonstrated impressive efficacy across multiple indications. However, concerns have emerged regarding their safety profile.

View Article and Find Full Text PDF

UGT2B7-mediated drug-drug interaction between cannabinoids and hydromorphone.

Drug Metab Dispos

July 2025

Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington; Division of Molecular Biosciences, Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York

Hydromorphone is a highly potent opioid used to treat severe chronic pain. It is metabolized primarily by UDP-glucuronosyltransferase (UGT)2B7 to form the inactive hydromorphone-3-glucuronide. Given that previous studies have shown that the major cannabinoids, Δ-tetrahydrocannabinol (THC) and cannabidiol (CBD), inhibit several UGT enzymes, the objective of the present study was to determine the inhibitory potential of major cannabinoids and their metabolites on UGT-mediated hydromorphone metabolism.

View Article and Find Full Text PDF

The aim of this Phase 1, multicentre, open-label study was to evaluate the safety, tolerability and pharmacokinetics (PK) of abemaciclib administered at global recommended Phase 2 dose (RP2D) of 200 mg twice daily, combined with standard doses of abiraterone and prednisolone, in Japanese patients with metastatic castration-resistant prostate cancer (mCRPC). Dose-limiting toxicities (DLTs) were assessed for 28 days post-first dose. Six patients were treated, and all experienced at least one treatment-emergent adverse event (TEAE), mostly low grade; no Grade 4 or 5 TEAEs occurred.

View Article and Find Full Text PDF

Preface to DMR drug-drug interactions special issue.

Drug Metab Rev

August 2025

Pharmacokinetics, Dynamics, Metabolism and Bioanalytics, Merck & Co., Inc, Boston, MA, USA.

View Article and Find Full Text PDF